Large-scale investigations aimed at elucidating the molecular mechanism of action of antidepressant treatment are achievable through the application of proteomic technologies. We performed a proteomic study on the Flinders Sensitive Line (FSL), a genetically selected rat model of depression, and the control Flinders Resistant Line (FRL). To evaluate gene-environment interactions, FSL and FRL animals were separated from their mothers for 3 h from postnatal days 2 to 14 (maternal separation ; MS), since early-life trauma is considered an important antecedent of depression. All groups received either escitalopram (Esc) admixed to food pellets (25 mg/kg.d) or vehicle for 1 month. Protein extracts from prefrontal/frontal cortex and hippocampus were separated by 2D electrophoresis. Proteins differentially modulated were identified by mass spectrometry. Bioinformatics analyses were performed to discover gene ontology terms associated with the modulated proteins. This paper was focused on the modifications induced by the environmental challenge of MS, both on the predisposed genetic background and on the resistant phenotype. The combination between Esc treatment and MS was investigated by comparing the MS, Esc-treated rats with rats subjected to each single procedure. In MS rats, antidepressant treatment influenced mainly proteins involved in carbohydrate metabolism in FSL rats and in vesicle-mediated transport in FRL rats. When studying the interaction between Esc and MS vs. non-separated rats, proteins playing a role in cytoskeleton organization, neuronal development, vesicle-mediated transport and synaptic plasticity were identified. The results provide further support to the available reports that antidepressant treatment affects intracellular pathways and also suggest new potential targets for future therapeutic intervention.
Introduction
Two major mechanisms of action account for the efficacy of available antidepressants : blockade of neurotransmitter re-uptake and the inhibition of its degradation (Anderson, 2000 ; Arroll et al. 2005 ; Papakostas et al. 2007) . Both mechanisms induce a short-term increase in the availability of monoaminergic neurotransmitters in the synaptic cleft. Nevertheless, since a delay of a few weeks is observed before therapeutic improvement occurs in patients, it is likely that a cascade of incompletely established molecular events occur in the longer-term to bring about therapeutic efficacy (Berton & Nestler, 2006) . The elucidation of the molecular mechanism of actions of available antidepressants is a key step in the direction of understanding the pathophysiological changes mediating major depressive disorder (MDD). This knowledge is also necessary in order to help design new, more efficacious medicines with an improved side-effect profile with respect to available antidepressants.
The aim of this work was to elucidate the molecular changes in protein expression in brain regions relevant for MDD after long-term treatment with escitalopram (Esc), a pro-serotonergic antidepressant. We employed the genetically selected Flinders Sensitive Line (FSL) model to model brain circuit dysregulations involved in depressive symptoms (Overstreet et al. 2005 ; Yadid et al. 2000) . As controls, we used Flinders Resistant Line (FRL) rats, which do not show the depressive-like behaviour. To evaluate gene-environment interactions, FSL and FRL pups were maternally separated (MS), as early-life trauma is considered an important antecedent of MDD (Brown & Moran, 1994 ; Hammen, 2005 ; Horesh et al. 2008) . Chronic pharmacological treatment was performed with Esc, a highly-selective SSRI (Murdoch & Keam 2005 ; Sanchez et al. 2003) .
A wide-scale analysis of protein expression was performed by a 2D proteomic approach. This study particularly focused on the influence exerted by MS in the modulation of protein expression after Esc treatment. A companion paper (Piubelli et al. 2010) was centred on the effects due to genetic background. Both investigations were performed within GENDEP, an integrated project financed by the EU combining large-scale clinical pharmacogenomic studies on depressed patients with preclinical investigations on animal disease models, focusing on treatment with antidepressants (Uher et al. 2010) .
Methods

Experimental design
FSL (total n=29) and FRL (total n=34) rats were maternally separated from postnatal day (PD) 2 to PD 14 (n=17, n=15 respectively). Control groups were not separated. Both stressed and control rats were split into groups receiving Esc or vehicle for 1 month (n=7-9/group ; Supplementary Fig. S1 , available online). Rats were then euthanized and protein extracts prepared from hippocampus (HC) and prefrontal/ frontal cortex (P/FC) for proteomic analysis in both brain regions. Image and statistical analyses were performed by comparing samples that belonged to the same electrophoretic run. In this paper, maps belonging to the following groups were compared : (i) FSL+MS+Esc vs. FSL+MS ; (ii) FRL+MS+Esc vs. FRL+MS ; (iii) FSL+MS+Esc vs. FSL+Esc ; (iv) FRL+MS+Esc vs. FRL+Esc.
In a companion paper (Piubelli et al. 2010) , additional comparisons were reported.
Maternal separation, pharmacological treatment, proteomics and bioinformatics analyses
These experimental procedures are fully described in the companion paper (Piubelli et al. 2010) .
Western blotting
Twenty micrograms of protein extracts were diluted with 5r Laemmli's sample buffer [300 mM Tris-HCl (pH 6.8), 50 % glycerol, 10 % SDS, 0.1 % Bromophenol Blue, 720 mM b-mercaptoethanol], incubated at 95 xC for 3 min and separated by SDS/polyacrylamide gel electrophoresis on 12 % T-0.8 % C acrylamide gels in Tris/glycine/SDS buffer. Proteins were then electroblotted onto polyvinylidene fluoride membranes (GE Healthcare, USA) at 400 mA for 3 h at 4 xC. Nonspecific sites were blocked by incubating with 5 % nonfat dried milk and 0.1 % Tween-20 (Sigma-Adrich, USA) in Tris-buffered saline for 2 h at room temperature. Membranes were incubated with primary antibodies (Supplementary Table 1 , online) in 3 % non-fat dried milk, 0.1 % Tween-20 in Tris-buffered saline overnight at 4 xC, washed, and incubated 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies (Table 1) . Immunocomplexes were detected by chemiluminescence (ECL, GE Healthcare) on X-ray X-Omat AR films (Kodak, USA). Membranes were immunoblotted again with a monoclonal anti-b actin antibody (Sigma-Adrich, 1 : 5000) for normalization. This antibody can be used for normalization purposes even when the investigated treatments affect actin levels because it recognizes the total amount of protein, which is abundant in cells, while the forms that are affected by experimental manipulation are low-abundance isoforms. The intensity of chemiluminescence response was measured by acquiring film images by VersaDoc and processing images with Quantity One 4.4 software (Bio-Rad, USA). Data were analysed with Student's t test using Microsoft Excel statistics tools.
Differential proteomics
Statistically significant differences in protein levels were detected in the comparisons between the experimental conditions examined. The numbers of significantly modulated spots are reported in Table 1 . In the first set of results, the effect of Esc treatment was evaluated in both strains and brain regions after MS. In the second set of comparisons, the interaction between Esc and MS was investigated by comparing Esc-treated, separated rats vs. ESC-treated nonseparated animals. Spots showing statistically significant changes were identified by peptide fingerprinting analysis, obtaining an overall success rate of protein identification of 68 % ; successful identifications in HC and P/FC are reported in Tables 2-5 . Protein names and accession numbers in the Uniprot database were shown, as well as the quantitative amount of regulation. In addition, gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway terms were also reported in the Tables to highlight the biological pathways mostly affected by the modulation.
Bioinformatic analysis
Bioinformatic analyses with the functional annotation tool in DAVID Bioinformatics Resources were performed to highlight which GO terms were significantly associated with the modulated proteins in each comparison.
In rats that were subjected to MS, Esc treatment induced a modulation of proteins mainly involved in energy metabolism in FSL rats (Fig. 1 a) and in the establishment of protein localization and in vesiclemediated intracellular transport in FRL rats (Fig. 1 b) . Among modulated proteins, the following can be pointed out in the FSL strain: pyruvate kinase, ATP synthase, triosephosphate isomerase, a-and b-tubulins, dihydropyrimidinase-related protein-2, b-actin, prohibitin and guanine nucleotide binding protein (Table 2 ). In the FRL strain, changes in the following proteins can be highlighted : 14-3-3 f/d and c, clathrin, dynamin 1, a-and b-tubulins, Erk2, syntaxin binding protein 1, septins, synapsin-1, spectrin, glia maturation factor, MARCKS, UCHL1, calbindin, cystatin B, fatty acid binding protein, Rho GDP dissociation inhibitor, glutamine synthetase (Table 3) .
In Esc-treated rats, the effect of MS influenced mainly proteins involved in cytoskeleton organization in FSL rats ( Fig. 1 c : b-and c-actin, neurofilament light chain, F-actin-capping protein, tropomyosin and DRP1 ; Table 4 ) and in vesicle-mediated transport in FRL rats (dynamin 1, synapsin-1, Fig. 1 d, Table 5 ).
Ingenuity pathway analyses allowed assessing which protein networks were influenced in the different comparisons. Figures 2 and 3 show the most relevant networks, ranked by percentage of experimentally detected proteins vs. total number of proteins in the network.
Western blotting
Based on 2D fold-change and availability of commercial antibodies, a number of proteins were progressed to Western blotting analysis. A summary of results is reported in Table 6 . The identities of modulated proteins are shown (column 3), with Uniprot accession numbers (column 2) and the standard spot number assigned by the image analysis software (column 1). When more than one spot was identified as the same protein, the respective parameters for each spot are indicated in the same raw and arranged according to the standard spot number of the spot. Experimental/ theoretical values of molecular mass (M r ) in Daltons (Da) and isoelectric point (pI) are reported in columns 4 and 5, respectively. Proteins were identified by Mascot search and also checked by Profound search. Mascot scores are shown in column 6 ; when a protein was identified only by Profound, the Profound expectation value (indicated by *) was reported. Number of identified peptides and sequence coverage are shown in columns 7 and 8, respectively. In column 9, results from statistical evaluations are reported as Student's t test/Partial Least Squares (PLS) analysis. If the spot was significant in Student's t tests, the p value is indicated or n.a. (not applicable) is reported when the spot was missing in one of the two gel groups. Spot significance by PLS analysis (>95 %) is indicated by a +. The size and direction of variation are indicated in the fold changes (FC) column 10. Changes with a large ratio (>100) have been arbitrarily assigned as >100 or f100, depending on the direction of the variation. In columns 11 and 12, Gene Ontology (GO) annotation (at biological process level 5 : GOTERM_BP_5) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway terms (when available) were associated using DAVID tools to each protein, in order to categorize them according to their function and the related cellular or disease pathways. When GO annotations were not available, molecular function from Uniprot was reported (in italics). 
Discussion
The aim of this work was to analyse the effect of Esc administration on protein levels in a rat model of MDD, incorporating both the genetic and environmental components. In this study, the focus was set on the changes induced by MS on both the sensitive and the resistant strains.
Influence of Esc with MS on genetic backgrounds
In the first set of data, the impact of exposure to MS in the response to antidepressant treatment was investigated. Protein pathways were differently modified in the two strains. The focus shifted to cellular carbohydrate metabolism in FSL rats and in cellular localization and intracellular transport in FRL rats, thus revealing a gene-environment interaction in the protein modulation (Fig. 1 ).
The networks identified by pathway analysis in FSL HC (Fig. 2) showed that proteins implicated in energy metabolism (e.g. pyruvate kinase, phosphoglycerate mutase, triosephosphate isomerase, carbonic anhydrase, APT synthase, etc.), and cellular functions maintenance (e.g. heat-shock proteins, DRP2) were mainly affected by Esc treatment after maternal separation. These pathways were also interconnected with actin and tubulin, proteins involved in cytoskeleton reorganization. Most enzymes involved in energy metabolism were also reported to be modified in a model of anxiety in the mouse (Szego et al. 2010) and to be affected by antidepressant treatment (Carboni et al. 2006) .
Interestingly, in FRL animals the regulation of clathrin suggests that antidepressant treatment may influence the regulation of synaptic vesicle recycling. In agreement, another protein involved in the regulation of synaptic vesicle docking and fusion, syntaxin binding protein 1, was also regulated.
In support of this interpretation, syntaxin binding protein 1 showed altered expression in the dorsolateral prefrontal cortex of schizophrenia and bipolar disorder patients (Behan et al. 2009 ). Moreover, this picture fits with the described role of chronic antidepressant treatment in stabilizing glutamate neurotransmission in the HC through modulation of the interactions between pre-synaptic proteins involved in the membrane fusion machinery (Bonanno et al. 2005) . Within this framework also fits the regulation of septin isoforms, ubiquitous cytoskeletal components that regulate neurotransmitter release in neurons, acting as scaffolds for presynaptic molecules, such as the dopamine transporter (Beites et al. 1999 ; Martinez & Ware, 2004 ; Son et al. 2005) . Several members of this protein family showed a dysregulation in the dorsolateral prefrontal cortex of bipolar disorder and schizophrenia patients (Pennington et al. 2008) , indicating an important role for this class of proteins in the pathophysiology of psychiatric disorders. The influence on vesicular transport pathways in FRL rats is well described in the network reported in Fig. 3 . In this network, most cytosolic and membrane proteins, centred on dynamin and synapsin, are directly or indirectly involved in the formation, fusion and recycling of synaptic vesicles, such as some components of the exocytotic soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) complex, responsible for synaptic vesicle fusion and neurotransmitter release. These findings confirm a modulation of the presynaptic exocytotic machinery by stress and by antidepressant treatment after stress exposure (Bisgaard et al. 2007 ; Musazzi et al. 2010) . Esc treatment after MS in FRL rats also modulated the levels of fructose aldolase C ; protein-L-isoaspartate O-methyltransferase, triosephosphate isomerase, and ubiquitin carboxyl-terminal hydrolase isozyme L1, in accord with results from a similar experimental paradigm performed on Sprague-Dawley rats (Marais et al. 2009 ).
Influence of MS exposure in response to Esc
In the second set of data, information was collected about protein modulation in response to chronic antidepressant treatment in animals with increased vulnerability induced by postnatal stress exposure compared to non-stressed animals. Again, both strains and brain regions were investigated. In FSL rats, the highest impact was found on proteins belonging to the actin cytoskeleton. Within this category, actin, and F-actin binding protein can be mentioned, as having already been examined in the previous comparison. In contrast, in FRL animals, synaptic transmission proteins were more significantly affected, as already observed in the previous section, levels of synapsin I, a synaptic vesicle phosphoprotein that regulates neurotransmitter release, were influenced by antidepressant treatment and MS exposure, involving mainly FRL rats (Tables 3 and 5 ). Variations in synapsin I expression levels and phosphorylation states have already been recognized both in animal models of depression, with and without antidepressant treatment, and in post-mortem studies in humans, corroborating the hypothesis that a disturbance of the regulation of synaptic function is involved in the molecular mechanism of depression. In rats, exposure to unpredictable chronic mild stress reduced synapsin I mRNA expression in prefrontal cortex, while antidepressant treatment reversed this alteration (Bessa et al. 2009 ). In the same model, a subfield-specific alteration was detected in HC for both the mRNA and protein levels, which correlated with depressivelike behaviours and could be reversed by chronic treatment with the glucocorticoid receptor antagonist mifepristone (Wu et al. 2007) . In male C57BL/6 mice (in contrast to BALB/c), hippocampal synapsin I mRNA levels were reduced by exposure to restraint stress. Interestingly, the atypical antidepressant tianeptine did not modify this reduction (Alfonso et al. -transporting, mitochondrial F0 complex, subunit d ; BDNF, brain-derived neurotrophic factor ; CA2, carbonic anhydrase II ; CDK5, cyclin-dependent kinase 5 ; CLIC4, chloride intracellular channel 4 ; DPYSL2, dihydropyrimidinase-like 2 ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase ; GDNF, glial cell derived neurotrophic factor ; GSK3B, glycogen synthase kinase 3 beta ; HSPD1, heat-shock 60-kDa protein 1 ; JRK, Jerky ; KCNJ11, ATP-sensitive inward rectifier potassium channel 11 ; MAP1B, microtubule-associated protein 1B ; NOS2A, nitric oxide synthase 2 ; NTF3, neurotrophin 3 ; PABPN1, poly(A) binding protein, nuclear 1 ; PARK2, E3 ubiquitin-protein ligase parkin ; PGAM1, phosphoglycerate mutase 1 ; PKM2, pyruvate kinase, muscle ; PLD2, phospholipase D2 ; PRL, prolactin ; ROCK2, Rho-associated, coiled-coil containing protein kinase 2 ; SEMA3A, semaphorin 3a ; TPI1, triosephosphate isomerase 1 ; TUBA1A, tubulin, alpha 1a ; TUBB2A, tubulin, beta 2A ; TUBG1, tubulin, gamma 1 ; VIM, vimentin ; WASF1, WAS protein family, member 1 ; YWHAZ, 14-3-3 zeta/delta. (f 2000-2010 Ingenuity Systems Inc., all rights reserved.) 2006). Chronic treatment with the antidepressants tranylcypromine, desipramine and fluoxetine had differential effects on synapsin-I mRNA expression in rat HC and cerebral cortex, with only tranylcypromine significantly reducing levels (Rapp et al. 2004) . In another depression model, learned helplessness, a complex regulation of the protein expression of synapsin I was detected in the HC : after an initial increase, 8 d of learned helplessness as well as imipramine and fluvoxamine treatment of naive rats induced a significant decrease, while antidepressant treatment did not modify learned helplessness-induced changes (Iwata et al. 2006) . Chronic antidepressant treatment with fluoxetine and reboxetine in rats was also reported /calmodulindependent protein kinase II ; DBNL, drebrin-like, DNM1, dynamin 1 ; DYRK1A, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A ; ERP29, endoplasmic reticulum protein 29 ; HTR2C, serotonin receptor 2C ; ITSN1, intersectin 1 ; KL, klotho ; MAPK1, mitogen-activated protein kinase 1 ; MARCKS, myristoylated alanine rich protein kinase C substrate ; NEFL, neurofilament, light polypeptide ; PACSIN1, protein kinase C and casein kinase substrate in neurons 1 ; PACSIN2, protein kinase C and casein kinase substrate in neurons 2 ; PFN2, profilin 2 ; Pld, phospholipase D ; RGS20, regulator of G-protein signalling 20 ; SEPT5, septin 5 ; SEPT7, septin 7 ; SH3GL1, SH3-domain GRB2-like 1 ; SH3GL3, SH3-domain GRB2-like 3 ; SHANK2, SH3 and multiple ankyrin repeat domains 2 ; SLC6A3, dopamine neurotransmitter transporter, member 3 ; SNAP25 ; synaptosomal-associated protein, 25 kDa ; SNPH, syntaphilin ; SORBS2, sorbin and SH3 domain containing 2 ; SPTAN1, spectrin, alpha ; SST, somatostatin ; STXBP1, syntaxin binding protein 1 ; SYN1, synapsin I ; TUBB2B, tubulin beta 2B. /calmodulin kinase II-dependent phosphorylation of synapsin I in synaptosomes and synaptic membranes, without reducing total synapsin I in the HC, leading to a modification of the readily releasable vesicle pool and ultimately glutamate release and synaptic plasticity (Barbiero et al. 2007 ).
In the same animal model as in this study, the investigation of isolated synaptic terminals showed that Ca 2+ /calmodulin kinase II-dependent phosphorylation of synapsin I was elevated in FSL rats compared to the FRL strain, whereas a marked reduction was induced by chronic Esc treatment or MS of FSL rats (Musazzi et al. 2010) . The relevance of synapsins in psychiatric disorders is also supported by the finding that total synapsin was decreased significantly in postmortem analyses of patients with schizophrenia and bipolar disorder in the HC ; in particular, reductions in syanpsin I levels were detected in bipolar disorder brains (Vawter et al. 2002) .
Dynamin 1 is a microtubule-associated protein that binds and hydrolyses GTP. It is specifically expressed in neurons, where it plays a role in synaptic vesicle recycling (Ferguson et al. 2007) . It has been reported that some antidepressants, e.g. sertraline, fluvoxamine, fluoxetine and paroxetine, can inhibit dynamin 1 GTPase activity in vitro, thus potentially modulating synaptic vesicle endocytosis, but citalopram does not share this activity (Otomo et al. 2008) . Nevertheless, our data suggest that an indirect effect may indeed be exerted on dynamin 1 by Esc treatment. In addition, our previous data showed that chronic treatment with an NK 1 receptor antagonist, GR205171, modulated dynamin 1 levels in rat P/FC (Carboni et al. 2006) .
Western blotting
We performed Western blotting analysis on selected proteins. This analysis should highlight spot intensity variations due to changes in protein expression levels with respect to variations due to shift in the balance between different post-translationally modified isoforms, which cannot be detected by Western blotting with standard antibodies (Farley & Link, 2009 ; Seo & Lee, 2004) . Our results showed that in 4/11 instances Western blotting analysis revealed a statistically significant modulation of the protein expression level. In the remaining cases, significant variations in the total amount of several proteins that were modulated in 2D gels could not be detected in Western blots, suggesting that most changes happened at the level of posttranslational modifications. Nevertheless, the possibility that a portion of the modulated proteins could result from Type 1 errors cannot be ruled out from the present results obtained in a large-scale investigation.
Conclusions
In this work, a detailed analysis of molecular changes in brain protein levels induced by treatment with a pro-serotonergic antidepressant was performed in a gene-environment interaction model of MDD in rats. The results suggested that a set of specific modifications could be observed in the different experimental settings, thus reproducing the known impact of these variables in pharmacological treatments in humans. In common among the distinct conditions, an overall influence could be detected upon protein pathways involved in cytoskeletal regulation, energy metabolism, neurotransmission and synaptic plasticity, supporting the hypothesis of the importance of these pathways in the therapeutic efficacy of antidepressants.
Note
Supplementary material accompanies this paper on the Journal's website (http ://journals.cambridge.org/ pnp).
